In an era where pharmaceutical companies, biotech firms, and public health organizations are racing to make smarter, faster, and more confident decisions, access to reliable disease data has never been more critical. The growing complexity of global disease landscapes — spanning oncology, rare conditions, immunology, respiratory disorders, and beyond — demands tools that go far...